Francisella tularensis (FT) is a category A bioterrorism agent and is the etiological agent of a multisyndromic disease known as tularemia. Tularemia is a rare bacterial zoonosis that ranges from a mild lymphadenopathy to a severe form, termed typhoidal tularemia. Typhoidal tularemia results from inhalation of bacteria, carries a 30-60% mortality rate, and is the predominant form of disease that would result from use of FT as a bioweapon. Although antibiotics are available to treat this disease, initial diagnosis is difficult, likely resulting in delay of treatment in the event of a bioterrorist attack. The only current method of prophylaxis is a poorly-defined attenuated live vaccine strain (LVS) which is not currently approved for general use and is unlikely to be licensed in the future due to safety concerns. The goal of the work described here is to develop a safe, effective cytokine-assisted vaccine against FT using a novel vaccine delivery vector based on replication-restricted recombinant vesicular stomatitis virus (?G-VSV).
Aim 1 will utilize a combination of proteomic/bioinformatic, expression cloning, and DNA-sequencing methodologies to identify novel T cell-reactive targets of FT. As high priority target proteins are identified, they will be incorporated into Aim 2 studies to determine their value as immunogens in cytokine-assisted vaccines.
Aim 2 will test the efficacy of ?G-VSV as a vector for delivery of cytokine adjuvant(s) in combination with exogenous or ?G-VSV-encoded FT immunogens. Both previously-identified and new targets identified in Aim 1 will be evaluated as vaccine immunogens. Immune responses will be quantitatively and qualitatively characterized in a rodent model of tularemia, and challenge trials will be performed to determine vaccine efficacy. As effective vaccine modalities are identified, complementary mixed-modality vaccines will be designed to allow for qualitative manipulation of the resulting immune responses. Bimodal vaccines will be designed to elicit multifunctional (B and T cell-mediated) systemic and mucosal immune responses that are protective against challenge with viable FT. The studies proposed here will provide new information that should lead to the development of a safe and efficacious vaccine for FT. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI061260-01
Application #
6818212
Study Section
Special Emphasis Panel (ZAI1-LR-M (M1))
Program Officer
Schaefer, Michael R
Project Start
2005-01-15
Project End
2009-12-31
Budget Start
2005-01-15
Budget End
2005-12-31
Support Year
1
Fiscal Year
2005
Total Cost
$584,179
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Jayakar, Himangi R; Parvathareddy, Jyothi; Fitzpatrick, Elizabeth A et al. (2011) A galU mutant of Francisella tularensis is attenuated for virulence in a murine pulmonary model of tularemia. BMC Microbiol 11:179
Bina, Xiaowen R; Miller, Mark A; Bina, James E (2010) Construction of a bioluminescence reporter plasmid for Francisella tularensis. Plasmid 64:156-61
Clinton, Shawn R; Bina, James E; Hatch, Thomas P et al. (2010) Binding and activation of host plasminogen on the surface of Francisella tularensis. BMC Microbiol 10:76
Thakran, Shalini; Li, Hanfen; Lavine, Christy L et al. (2008) Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer. J Biol Chem 283:3751-60
Bina, Xiaowen R; Lavine, Christy L; Miller, Mark A et al. (2008) The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system that is required for virulence in mice. FEMS Microbiol Lett 279:226-33
Lavine, Christy L; Clinton, Shawn R; Angelova-Fischer, Irena et al. (2007) Immunization with heat-killed Francisella tularensis LVS elicits protective antibody-mediated immunity. Eur J Immunol 37:3007-20
Bina, Xiaowen R; Wang, Chunmei; Miller, Mark A et al. (2006) The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics. Arch Microbiol 186:219-28